Stella Pharma Corporation (TYO:4888)
Japan
· Delayed Price · Currency is JPY 405.00
+5.00 (1.25%)
Mar 25, 2025, 3:30 PM JST
Stella Pharma Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 |
| Cash & Equivalents | 3,452 | 2,052 | 2,710 | 3,276 | 1,251 | 2,007 | Upgrade
|
| Short-Term Investments | - | 300 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 3,452 | 2,352 | 2,710 | 3,276 | 1,251 | 2,007 | Upgrade
|
| Cash Growth | 34.90% | -13.21% | -17.28% | 161.87% | -37.67% | -32.90% | Upgrade
|
| Accounts Receivable | 93 | 76 | 59 | 16 | 55 | - | Upgrade
|
| Other Receivables | - | - | - | - | - | 41 | Upgrade
|
| Receivables | 93 | 76 | 59 | 16 | 55 | 41 | Upgrade
|
| Inventory | 1,272 | 1,116 | 940 | 773 | 392 | 305 | Upgrade
|
| Prepaid Expenses | 59 | 40 | 39 | 36 | 40 | 46 | Upgrade
|
| Other Current Assets | 22 | 45 | 44 | 74 | 72 | 2 | Upgrade
|
| Total Current Assets | 4,898 | 3,629 | 3,792 | 4,175 | 1,810 | 2,401 | Upgrade
|
| Property, Plant & Equipment | 65 | 81 | 102 | 92 | 68 | 68 | Upgrade
|
| Long-Term Investments | 63 | 57 | 371 | 382 | 89 | 100 | Upgrade
|
| Other Intangible Assets | 51 | 52 | 61 | 68 | 79 | 90 | Upgrade
|
| Other Long-Term Assets | - | 1 | 3 | 1 | 2 | 1 | Upgrade
|
| Total Assets | 5,077 | 3,820 | 4,329 | 4,718 | 2,048 | 2,660 | Upgrade
|
| Accounts Payable | 15 | 75 | 49 | 48 | 62 | 23 | Upgrade
|
| Accrued Expenses | 7 | 4 | 6 | 2 | 47 | 74 | Upgrade
|
| Current Portion of Long-Term Debt | 160 | 160 | 160 | 160 | 160 | 160 | Upgrade
|
| Current Income Taxes Payable | 47 | 212 | 202 | 92 | 45 | 44 | Upgrade
|
| Other Current Liabilities | 8 | 4 | 4 | 6 | 5 | 6 | Upgrade
|
| Total Current Liabilities | 237 | 455 | 421 | 308 | 319 | 307 | Upgrade
|
| Long-Term Debt | 653 | 773 | 933 | 1,093 | 1,253 | 1,413 | Upgrade
|
| Other Long-Term Liabilities | 1,155 | 163 | 176 | 187 | 200 | 213 | Upgrade
|
| Total Liabilities | 2,103 | 1,444 | 1,577 | 1,639 | 1,818 | 1,970 | Upgrade
|
| Common Stock | 2,859 | 2,938 | 3,300 | 3,808 | 1,999 | 1,900 | Upgrade
|
| Additional Paid-In Capital | 489 | 195 | 220 | 1,908 | 99 | - | Upgrade
|
| Retained Earnings | -373 | -763 | -778 | -2,636 | -1,869 | -1,209 | Upgrade
|
| Comprehensive Income & Other | -1 | 6 | 10 | -1 | 1 | -1 | Upgrade
|
| Shareholders' Equity | 2,974 | 2,376 | 2,752 | 3,079 | 230 | 690 | Upgrade
|
| Total Liabilities & Equity | 5,077 | 3,820 | 4,329 | 4,718 | 2,048 | 2,660 | Upgrade
|
| Total Debt | 813 | 933 | 1,093 | 1,253 | 1,413 | 1,573 | Upgrade
|
| Net Cash (Debt) | 2,639 | 1,419 | 1,617 | 2,023 | -162 | 434 | Upgrade
|
| Net Cash Growth | 66.39% | -12.25% | -20.07% | - | - | -68.80% | Upgrade
|
| Net Cash Per Share | 80.75 | 45.81 | 56.00 | 72.04 | -8.09 | 27.82 | Upgrade
|
| Filing Date Shares Outstanding | 34.04 | 31.22 | 29.48 | 28.65 | 20.14 | 15.6 | Upgrade
|
| Total Common Shares Outstanding | 34.04 | 31.22 | 29.48 | 28.65 | 20.14 | 15.6 | Upgrade
|
| Working Capital | 4,661 | 3,174 | 3,371 | 3,867 | 1,491 | 2,094 | Upgrade
|
| Book Value Per Share | 87.38 | 76.10 | 93.35 | 107.48 | 11.42 | 44.23 | Upgrade
|
| Tangible Book Value | 2,923 | 2,324 | 2,691 | 3,011 | 151 | 600 | Upgrade
|
| Tangible Book Value Per Share | 85.88 | 74.43 | 91.28 | 105.10 | 7.50 | 38.46 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.